US 11807649
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
granted A61PA61P35/02
Quick answer
US patent 11807649 (Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2) held by EnLiven Therapeutics, Inc. expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- EnLiven Therapeutics, Inc.
- Grant date
- Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 44
- CPC classes
- A61P, A61P35/02